DexCom (DXCM) Stock Forecast & Price Target

DexCom is supported by a durable fundamental case built on leadership in continuous glucose monitoring, expanding use beyond intensive insulin users into the large Type 2 non-insulin market, and a scalable, profitable model with significant upside from broader adoption. The CONNECT RCT was especially compelling, showing a 6-month A1c reduction of -1.6% versus -0.7% for control, ~21% time-in-range improvement, and ~97% adherence, while real-world data tied CGM use to lower cardiovascular events and mortality. Software-driven engagement from Stelo, NutriSense integration, and easier app-based coaching should support retention and utilization, while anticipated CMS expansion and international rollout provide additional long-term growth catalysts.

DexCom is facing material product and market risks that weaken the investment case, starting with sensor-related compression lows that can distort overnight glucose readings and limit the practicality of its CGM system for side sleepers. Beyond product performance, the diabetes device sector is exposed to regulatory delays, pricing pressure from payors and CMS, and heavy investment needs, all of which can make sustained profitability difficult despite demand growth. The bearish outlook is reinforced by the risk that CGM penetration may not increase, competitive products could erode DexCom’s moat, new releases may be delayed by regulatory hurdles, and the stock may continue to trade at a significant premium multiple.